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Background: Hepatocellular carcinoma (HCC) is one of the most common types of cancer worldwide. Despite
several efforts to elucidate molecular mechanisms involved in this cancer, they are still not fully understood.
Methods: To acquire further insights into the molecular mechanisms of HCC, and to identify biomarkers for early
diagnosis of HCC, we downloaded the gene expression profile on HCC with non-cancerous liver controls from the
Gene Expression Omnibus (GEO) and analyzed these data using a combined bioinformatics approach.
Results: The dysregulated pathways and protein-protein interaction (PPI) network, including hub nodes that
distinguished HCCs from non-cancerous liver controls, were identified. In total, 29 phenotype-related differentially
expressed genes were included in the PPI network. Hierarchical clustering showed that the gene expression profile
of these 29 genes was able to differentiate HCC samples from non-cancerous liver samples. Among these genes,
CDC2 (Cell division control protein 2 homolog), MMP2 (matrix metalloproteinase-2) and DCN (Decorin were the hub
nodes in the PPI network.
Conclusions: This study provides a portfolio of targets useful for future investigation. However, experimental
studies should be conducted to verify our findings.
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Hepatocellular carcinoma (HCC), a primary liver cancer,
is the fifth most common cancer worldwide and the third
most common cause of cancer mortality [1]. An estimated
748,300 new liver cancer cases and 695,900 cancer deaths
occurred worldwide in 2008 [2]. This disease is most
prevalent in eastern and southeastern Asia, and in middle
Africa, with more than half of patients with HCC being
reported from China [3]. In addition, evidence has been
accumulating in various countries that the incidence of
HCC is rising [4-7]. To improve treatment and prognosis
of HCC, information about the phenotypic and molecular* Correspondence: lishaolin@cqmu.edu.cn; sheisawoman@163.com
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reproduction in any medium, provided the orchanges associated with the development of this disease
should be determined.
Much is known about the causes and development of
HCC. The main causative agents, hepatitis B virus (HBV),
hepatitis C virus (HCV), and aflatoxin B1, together
account for about 80% of all HCCs in humans [1,8-11].
Hepatocarcinogenesis is a complex process associated
with the accumulation of genetic and epigenetic changes
that occur during initiation and progression of the cancer.
In recent years, a number of genomic studies have identi-
fied genes that are uniquely upregulated or downregulated
in HCC tissues. For example, Lee et al. suggested that
cystatin B (CSTB) or the combination of CSTB and α-
fetoprotein may be useful markers for diagnosis with high
sensitivity of patients with HCC [12]. In addition, potential
biomarkers for detection of early HCC [13], such asLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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12 (ADAM12) [15], serine/threonine kinase 15 (STK15),
phospholipase A2 (PLA2) [16], and heat-shock protein
70 (HSP70) [17] have also been suggested by previous
studies. However, despite several previous efforts, the
current understanding or early diagnosis of HCC is still
rather limited.
The advancement of microarray technology now enables
elucidation of the molecular mechanism of HCC develop-
ment and identification of novel diagnostic biomarkers. In
this study, to acquire further insights into the molecular
mechanisms of HCC, we downloaded gene expression
profiles of 10 HCCs and 10 noncancerous liver controls
from the Gene Expression Omnibus (GEO) database, and
analyzed those data using bioinformatics tools. We identi-
fied a set of interactive genes that were significantly
downregulated or upregulated in HCC. These data
may help to improve the diagnostic accuracy of HCC.
Methods
Microarray data
The gene expression profiles of HCC with non-cancerous
liver controls, which were deposited by Deng and colleagues
(accession number: GSE19665,) (approved by ethics com-
mittee of Mianyang Central Hospital) were downloaded
from GEO [18]. The mRNA expression in ten HCCs (five
HBV-related and five HCV-related HCCs) and the 10
matched non-cancerous liver samples (five HBV-related
and five HCV-related chronic hepatitis or cirrhosis) was an-
alyzed byoligonucleotide arrays (GeneChip Human Genome
U133 plus 2.0; Affymetrix Inc., Santa Clara, CA, USA). For
global normalization, the average signal in an array was
made equal to 100. We downloaded the raw CEL data and
the annotation file for the platform.Protein-protein interaction data
A total of 36,289 pairs of protein-protein interactions (PPIs)
were downloaded from the Human Protein Reference
Database (HRPD; http://www.hprd.org/) [19] in March,
2011. Of these, 34,704 pairs of PPIs have relationships with
expression profiles. Data preprocessing and identification of
differentially expressed genes.
The Affy package in R [20,21] was used to preprocess
the raw expression data. We first converted the probe-
level data in the CEL files into expression measures. For
each sample, the expression values of all probes for a given
gene were reduced to a single value by taking the average
expression value; this yielded a set of 19,803 genes. The
Significance Analysis of Microarrays (SAM) software [22]
was used to identify differentially expressed genes (DEGs).
We considered a false discovery rate (FDR, corrected by
the Benjamini and Hochberg method [23]) of less than
0.01 to be significant.Functional enrichment tests
The Kyoto Encyclopedia of Genes and Genomes (KEGG)
pathway database records networks of molecular interac-
tions in the cells, and variants of these interactions specific
to particular organisms [24]. To explore the dysfunctional
pathways in HCC, we inputted the candidate genes into
the Database for Annotation, Visualization, and Integrated
Discovery (DAVID; http://david.abcc.ncifcrf.gov/) for path-
way enrichment analysis. DAVID is a web-based software
suite designed to categorize complex, high content, gen-
omic and proteomic datasets [25]. FDR <0.05 was selected
as the cut-off criterion.Construction of the PPI network
First, we identified phenotype-related genes by calculating
the Pearson correlation coefficient (r). The genes that
showed significant correlation with HCC (r >0.8 or r < −0.8)
were selected as phenotype-related genes. The phenotype-
related genes and DEGs were then intersected to obtain the
phenotype-related DEGs. Meanwhile, we filtered the signifi-
cant PPIs in the HPRD database with a cut-off criterion of
r >0.8 or r < −0.8. Finally, we mapped the phenotype-related
genes for HCC to the significant PPIs, and constructed a
PPI network using Cytoscape software [26].Results
Identification of DEGs
The gene expression profile of GSE19665 was downloaded
from the GEO database and theSAM method was used to
identify DEGs in HCC compared with non-cancerous con-
trols. At FDR <0.01, 2,767 genes were identified as DEGs.
Of these, 1,359 genes (49.11%) were upregulated and the
remaining 1,408 genes (50.89%) were downregulated.Functional enrichment tests
To functionally classify these 2,767 significant genes, we
used the online biological classification tool DAVID, and
found significant enrichment of these genes in three path-
ways (Table 1). The most significant pathway was the cell
cycle with FDR = 0.0130. The other significant pathways
were complement and coagulation cascades (FDR =
0.0214) and DNA replication (FDR = 0.0251).
Further, we performed pathway enrichment analysis
separately for the upregulated and downregulated genes.
The 1,359 upregulated genes were enriched to 12 path-
ways (Table 2), including cell cycle, DNA replication,
base excision repair, and nucleotide excision repair,
while the 1,408 downregulated genes were enriched to 9
pathways (Table 3), including complement and coagula-
tion cascades, chemokine signaling pathway, and
cytokine-cytokine receptor interaction.
Table 1 The enriched pathways for differentially expressed genes (FDR < 0.05)
Pathway ID Pathway name Gene count P FDR
hsa04110 Cell cycle 121 1.37E-04 0.0130
hsa04610 Complement and coagulation cascades 67 1.13E-04 0.0214
hsa03030 DNA replication 36 3.99E-04 0.0251
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In total, 314 phenotype-related genes were identified with
r > 0.8 or r < −0.8. Most of these genes were DEGs be-
tween HCCs and noncancerous liver samples, except for
ISCA2 (iron-sulfur cluster assembly 2 homolog).
There were 399 pairs of PPIs filtered from HPRD with
r > 0.8 or r < −0.8. By mapping the phenotype-related
DEGs to these PPI data, we obtained 24 pairs of PPIs,
including 29 nodes (Figure 1). We found that CDC2
(Cell division control protein 2 homolog), MMP2
(matrix metalloproteinase-2) and DCN (Decorin) were
hub nodes in the PPI network, suggesting that these
genes may play important role in the initiation of HCC.Hierarchical clustering
To verify whether the 29 genes in the PPI network could
be used to differentiate between HCC and non-cancerous
liver, we performed hierarchical clustering using R based
on gene expression level (Figure 2). We found that al-
though the 29 gene profiles could notdifferentiate HCV-
related HCCs from HBV-related HCCs, they could
differenttiate HCC samples from non-cancerous livers. In
addition, hierarchical clustering portioned the genes into
two groups. In total, 15 genes were upregulated in HCC,
including THBS1 (Thrombospondin 1), IGFBP3 (insulin-
like growth factor binding protein 3), GPRASP1 (G protein-
coupled receptor associated sorting protein 1), DPT
(dermatopontin), and MMP2. The other 14 genes were
downregulated in HCC, and included TUBG1 (tubulin,Table 2 The enriched pathways for up-regulated genes (FDR<




hsa03410 Base excision repair
hsa03420 Nucleotide excision repair
hsa00970 Aminoacyl-tRNA biosynthesis





hsa04914 Progesterone-mediated oocyte maturationgamma 1), CDKN2C (Cyclin-dependent kinase 4 inhibitor
C), CDKN2A and RRM2 (ribonucleotide reductase M2).
Discussion
Although previous studies have generated a large number
of biomarkers for early diagnosis of HCC, the efficiency of
current therapy of patients with this disease is still low. In
addition, the molecular mechanism of HCC is still not fully
understood. In this study, we analyzed the gene expression
profile of HCC and non-cancerous liver samples using a
combined bioinformatics approach. The dysregulated path-
ways and PPI network, including hub nodes that distin-
guished HCCs from noncancerous liver controls, were
identified.
Our approach identified an HCC molecular signature of
29 genes. Hierarchical clustering showed that the gene ex-
pression profile of these 29 genes was able to differentiate
HCC samples from noncancerous livers. Of these genes,
CDC2, MMP2, and DCN were hub nodes in the PPI net-
work. Studies suggest that more centralized genes in the
network are more likely than peripheral genes to be key
drivers of proper cellular function [27].
CDC2, also known as CDK1, is a member of the serine/
threonine protein kinase family. This protein is a catalytic
subunit of the highly conserved protein kinase complex
known as M-phase promoting factor, which is essential for
G1/S and G2/M phase transitions of the eukaryotic cell
cycle. In our study, CDC2 was differentially expressed in
HCC compared with noncancerous lives. A previous study
suggested that CDC2 plays the most crucial role of the0.05)













Table 3 The enriched pathways for down-regulated genes (FDR < 0.05)
Pathway ID Pathway name Down genes P FDR
hsa04610 Complement and coagulation cascades 27 1.37E-09 2.31E-07
hsa04062 Chemokine signaling pathway 43 2.53E-07 2.14E-05
hsa04060 Cytokine-cytokine receptor interaction 54 4.37E-07 2.46E-05
hsa04640 Hematopoietic cell lineage 24 9.55E-06 4.03E-04
hsa00590 Arachidonic acid metabolism 17 6.48E-05 0.0022
hsa05020 Prion diseases 12 5.63E-04 0.0157
hsa05340 Primary immunodeficiency 12 7.43E-04 0.0178
hsa04672 Intestinal immune network for IgA production 14 7.84E-04 0.0164
hsa04510 Focal adhesion 35 0.0026 0.0484
Zhang et al. European Journal of Medical Research 2013, 18:35 Page 4 of 7
http://www.eurjmedres.com/content/18/1/35G2/M modulators in cell cycle progression and cell prolif-
eration of HCC, and significantly predicts the recurrence
of this carcinoma [28]. Another study showed that CDC2
and CDK2 are activated in HCC, and this may be due to a
complex interplay between the level of cyclin, CDK, CDK
inhibitors, and inhibitory phosphorylation [29]. In accord-
ance with this study, our PPI network showed that CDC2
directly interacted with CCNB1, CCNB2, and CDKN3. In
addition, FOXM1 (Forkhead box protein M1), TOP2A,
RRM2, and ECT2 were also identified as having interac-
tions with CDC2. FOXM1 is a human cell cycle transcrip-
tion factor that is known to play a key role in regulating
timely mitotic progression and chromosomal segregation
during cell division [30]. Xia et al. reported that activation
of FOXM1 through the ERK/CREB pathway is involved in
HBV-related hepatocarcinogenesis [31]. Overexpression of
TOP2A was reported to be correlated with earlier onset,Figure 1 CDC2, MMP2, and DCN are hub nodes in the protein-protein
differentially expressed genes (DEGs).shorter survival time, and resistance to chemotherapy in
HCC [32]. RRM2 is located in a region of frequent cyto-
genetic aberration in HCC [33]. Chua et al. suggested that
gallium maltolate might be a promising chemotherapeutic
agent for treatment of HCC by targeting RRM2 [34].
MMP2 is a key member of the matrix metalloproteinase
(MMP) family, which is involved in many pathological con-
ditions, particularly cancer metastasis and angiogenesis
[35,36]. Our result suggested that MMP2 is upregulated
in HCC, and this result is in line with previous studies
[37-41]. The PPI network in our study showed that MMP2
directly interacted with six DEGs: TIMP2, CXCL12, DCN,
FGFR1, THBS1, and IGFBP3. TIMP2 is the tissue inhibitor
of MMP2. An imbalance between the proteolytic activity of
MMP2 and TIMP2 is responsible for degradation of extra-
cellular matrix (ECM) components, and plays a crucial role
in tumor invasion and in metastasis formation [42]. Theretinteraction (PPI) network constructed by phenotype related
Figure 2 Hierarchical clustering of genes in the protein-protein interaction (PPI) network. Rows represent genes and columns represents
sample. The samples under the green bar were noncancerous liver samples and the samples under the purple bar were hepatocellular (HCC) samples.
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and MMP2 and TIMP2 mRNA levels, as well as with
MMP2 activation in HCCs [43]. THBS1 is a matricellular
protein capable of modulating angiogenesis, and high ex-
pression of THBS1was shown to be associated with tumor
invasiveness and progression in HCC [44]. IGBP-3 is a me-
diator of growth suppression signals and a putative tumor
suppressor. It was reported that IGFBP-3 mediates growth
suppression signals via the transforming growth factor-β
and/or Rb pathways in HCC [45].
DCN is a small cellular or pericellular matrix proteogly-
can that is closely related in structure to biglycan protein.
Our result suggested that DCN is differentially expressed
in HCC and interacts with DPT, THBS1, MMP2 and
COL14A1. Few studies have reported DCN expression in
HCC, therefore its potential role in hepatocarcinogenesis
remains to be investigated. In addition, increased expression
levels of S100A8 and S100A9 have been detected in various
human cancers in recent years [46]. Nemeth et al. suggest
that S100A8 and S100A9 are novel nuclear factor-κB target
genes in HCC cells, and increased expression of theseproteins supports malignant progression by activation of re-
active oxygen species-dependent signaling pathways [47].
There are some limitations to our study. First, we did not
generate the microarray data ourselves but took them from
the GEO database. Second, as differences exist between
HBV-related and HCV-related cancers, elaboration of HBV-
specific or HCV-specific genes may be more important.
Third, validation of the results in other datasets or samples
is lacking in this study, therefore, further experimental stud-
ies based on a larger sample size are needed to confirm our
results. This would be the next step in our research.Conclusion
In conclusion, we have identified an HCC molecular signa-
ture of 29 genes. Of these genes, CDC2, MMP2, and DCN
were hub nodes in the PPI network. However, further ex-
perimental studies are necessary to confirm our results and
to elucidate the role of these genes in HCC pathogenesis
and to determine their potential as molecular targets for
the development of new therapeutic approaches for HCC.
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